Compare ELME & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | PLX |
|---|---|---|
| Founded | 1960 | 1993 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 230.0M |
| IPO Year | N/A | N/A |
| Metric | ELME | PLX |
|---|---|---|
| Price | $2.17 | $2.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.25 | $12.00 |
| AVG Volume (30 Days) | ★ 5.6M | 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 33.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $43.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $1.32 |
| 52 Week High | $17.68 | $3.10 |
| Indicator | ELME | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 8.35 | 72.63 |
| Support Level | $2.15 | $2.81 |
| Resistance Level | $2.26 | $3.03 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.51 | 0.03 |
| Stochastic Oscillator | 46.88 | 93.00 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.